Côd QR

TRK Inhibition with Entrectinib in Metastatic Salivary Secretory Carcinoma (SC): A Case Report

NTRK gene fusions are rare oncogenic driver mutations that can be found in a broad range of neoplasms. In secretory carcinoma (SC), <i>ETV6-NTRK3</i> gene fusion is seen in a majority of the cases and represents a druggable target for patients with advanced disease in the absence of a currently acce...

Disgrifiad llawn

Wedi'i Gadw mewn:
Prif Awduron: Matthew S. Ernst, John T. Lysack, Martin D. Hyrcza, Shamir P. Chandarana, Desiree Hao
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: MDPI AG 2022-05-01
Cyfres:Current Oncology
Pynciau:
secretory carcinoma
NTRK
entrectinib
larotrectinib
targeted therapy
molecular testing
Mynediad Ar-lein:https://www.mdpi.com/1718-7729/29/6/314
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg